Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Director · Chief Executive Officer | August 13, 2018 | August 15, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date August 13, 2018 · Filed August 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 698,056 |
Reported balance
After 2018-08-13 transaction · row 1
1 source rowRow 1 · 2018-08-13 · Grant · Acquired 200,000 · Balance 698,056 F1: Represents the issuance of restricted stock units (the "RSUs"). The RSUs vest and become exercisable as follows: (i) 50% of the RSUs will vest on December 15, 2018 and (ii) 50% of the RSUs will vest on December 15, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the issuance of restricted stock units (the "RSUs"). The RSUs vest and become exercisable as follows: (i) 50% of the RSUs will vest on December 15, 2018 and (ii) 50% of the RSUs will vest on December 15, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2018 Filed Aug 15, 2018 22:55 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-046889 · doc4.xml · nonDerivative · entry 1 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 698,056 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). The RSUs vest and become exercisable as follows: (i) 50% of the RSUs will vest on December 15, 2018 and (ii) 50% of the RSUs will vest on December 15, 2019. Read SEC document |
| February 26, 2018 Filed Mar 1, 2018 00:16 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Options (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-18-014696 · doc4.xml · derivative · entry 1 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2023-02-26 F1 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable in four equal quarterly installments beginning on May 26, 2018. Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 22:38 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 11,323 | $0.90 | $10,190.70 |
DisclosureSEC source: 0001209191-18-003458 · doc4.xml · nonDerivative · entry 5 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,056 Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 22:38 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 9,000 | $0.94 | $8,460.00 |
DisclosureSEC source: 0001209191-18-003458 · doc4.xml · nonDerivative · entry 4 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,379 Read SEC document |
| January 12, 2018 Filed Jan 12, 2018 22:38 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 677 | $0.93 | $629.61 |
DisclosureSEC source: 0001209191-18-003458 · doc4.xml · nonDerivative · entry 3 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,379 Read SEC document |
| January 11, 2018 Filed Jan 12, 2018 22:38 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 2,000 | $0.94 | $1,880.00 |
DisclosureSEC source: 0001209191-18-003458 · doc4.xml · nonDerivative · entry 2 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 519,056 Read SEC document |
| January 10, 2018 Filed Jan 12, 2018 22:38 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 18,500 | $0.94 | $17,390.00 |
DisclosureSEC source: 0001209191-18-003458 · doc4.xml · nonDerivative · entry 1 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,056 Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 20:53 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Options (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001209191-17-041851 · doc4.xml · derivative · entry 2 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2027-06-22 F2 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on December 31, 2018 with the remaining shares vesting in 3 equal annual installments thereafter. Read SEC document |
| June 22, 2017 Filed Jun 26, 2017 20:53 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon Stock | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041851 · doc4.xml · nonDerivative · entry 1 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 539,556 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). 25% of the RSUs vest on December 31, 2018 with the remaining shares vesting in 3 equal annual installments thereafter. Vested shares will be delivered to the Reporting Person on the earlier of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee's Service ceases for any reason and such cessation constitutes a "separation from service" within the meaning of Section 409A of the Code; (iii) the date of Grantee's death or (iv) the date of a Change in Control that constitutes a "change in control event" within the meaning of Section 409A of the Code. Read SEC document |
| April 12, 2017 Filed Apr 13, 2017 23:39 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 1,500 | $0.95 | $1,425.00 |
DisclosureSEC source: 0001209191-17-026950 · doc4.xml · nonDerivative · entry 2 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,556 Read SEC document |
| April 11, 2017 Filed Apr 13, 2017 23:39 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | SaleCommon Stock | 1,801 | $0.95 | $1,710.95 |
DisclosureSEC source: 0001209191-17-026950 · doc4.xml · nonDerivative · entry 1 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,056 F1 · balance_after: Reflects the cancellation of 500,000 Restricted Stock Units pursuant to an RSU Cancellation Agreement, dated December 13, 2016. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 23:24 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001209191-17-017983 · doc4.xml · derivative · entry 1 Lambert Henry R. · CIK 0001587257 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-03-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on April 30, 2017, July 31, 2017, October 31, 2017 and January 31, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.